143 results about "Pancreatic islet cell" patented technology

Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

The invention relates to a heparinized gelatin / sodium alginate pancreas islet packaging material with an anti-fibrosis function as well as a preparation method and application of the heparinized gelatin / sodium alginate pancreas islet packaging material. The preparation method comprises the following steps: adding gelatin into normal saline, soaking, performing autoclaved sterilization to obtain a gelatin solution, then adding epsilon-polylysine hydrochloride into the gelatin solution, and finally adding glutamine transaminase for reaction to obtain an epsilon-polylysine grafted gelatin solution; adding heparin into the solution, and reacting to obtain a heparinized gelatin solution; adding sodium alginate and glutamine transaminase, reacting, diluting, preparing hydrogel microspheres by adopting an electrostatic spraying method, and cross-linking to obtain the hydrogel microspheres. According to the invention, heparin molecules are incorporated into a pancreas islet packaging system, so that fibrosis at the periphery of the microspheres can be relieved, the pancreas islet cells are packaged by using the pancreas islet packaging material to prepare the biological artificial pancreas, the pancreas islet cell proliferation and insulin secretion can be promoted, and the pancreas islet packaging material has a good diabetes treatment effect.

Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some embodiments, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some embodiments, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

The invention relates to the technical field of biological pharmacy, in particular to application of a recombinant protein DEL-1 in preparation of a medicine for resisting pancreatic beta cell inflammation. The recombinant protein DEL-1 has a remarkable inhibition effect on pancreatic beta cell inflammatory response induced by high glucose and high fat. Experiments show that in an islet beta cell inflammation model constructed by combining high glucose with palmitic acid, DEL-1 can significantly reduce the expression level of inflammatory factors such as IL-1beta, IL-6, TNF-alpha and the like. The DEL-1 is proved to have a definite effect of resisting pancreatic beta cell inflammation.

The invention belongs to the technical field of polysaccharide extraction, and particularly relates to mesona chinensis polysaccharide with glycometabolism regulating activity, which is prepared by the steps of micro-fermentation drying, raw material pretreatment, pulping, targeted extraction of polysaccharide, primary separation of polysaccharide, secondary separation of polysaccharide, polysaccharide purification, polysaccharide drying and the like. The mesona chinensis polysaccharide prepared by the method disclosed by the invention has good effects of inhibiting the activity of alpha-glucosidase, improving pancreas beta cell injury and the like, i.e., the mesona chinensis polysaccharide has relatively strong glucosyl metabolism regulating activity.

The invention discloses a long-acting GGG three-target agonist, and the compound provided by the invention simultaneously achieves nM-level excellent agonist ability on three targets of GLP-l / GIP / GCGR, and can fully excite corresponding target organ tissue cells. The compound provided by the invention can promote insulin secretion and reduce blood sugar; in addition, ingestion can be inhibited, gastric emptying can be delayed, energy consumption can be increased, and finally the weight reduction effect can be observed. The compound provided by the invention can reduce pancreatic beta-cell apoptosis, increase the quantity of pancreatic beta-cells and improve functions of pancreatic cells. The compound disclosed by the invention can also improve blood fat, reduce liver fat accumulation and inhibit liver inflammation development. The compound or the composition can be used for preventing and / or treating metabolic disorder diseases and related complications thereof. The compound or the composition can be used for treating bone diseases related to endocrine diseases, metabolic disorders, nephropathy and the like, such as osteoporosis and osteoarthritis.

The present application relates to a kind of platform for three-dimensional organoid culture of islet, comprising: 0.15-0.3 w / v self-assembled polypeptide derivative hydrogel.The platform of the present application, the islet organoid of the method for preparing three-dimensional organoid of islet by the platform can maintain its cell integrity, not broken, and does not affect the secretion of insulin.Meanwhile the hydrogel can exist in mouse for a long time, lay a foundation for long-term enhancement of islet beta cell vitality and function.

The invention relates to the technical field of gene vectors, and discloses a multi-target multi-gene stable silencing vector and an application thereof in treating diabetes mellitus, and a multi-gene multi-target gene modification combined element is safely and efficiently integrated at a gene safety parking point of a second intron region of a CCR5 gene in a genome in a reverse fixed point manner by using a non-viral vector system; therefore, the effect of continuously silencing expression of a plurality of target genes such as MSTN, GRB10 and PTBP1 for a long time is achieved, and aging of mesenchymal stem cells cultured in vitro is remarkably inhibited. When the mesenchymal stem cells modified by the multi-target multi-gene stable silencing vector are infused, the activity is high, the chronic inflammatory microenvironment is effectively inhibited, and the senescence process is delayed; moreover, proliferation and differentiation of pancreatic beta cells are promoted, insulin secretion is enhanced, insulin resistance is effectively resisted, and diseases such as diabetes mellitus are prevented.

The invention discloses nutrition-balanced flour assisting in pancreas islet repair as well as a preparation method and application of the nutrition-balanced flour. The nutrition-balanced flour is prepared from the following raw materials in parts by mass: 40-60 parts of whole grains, 10-15 parts of beans, 5-15 parts of vital gluten, 7-10 parts of potatoes, 7-10 parts of vegetables, 5-8 parts of bacteria and algae, 5-8 parts of nut seeds, 3-5 parts of medicinal and edible food and 3-5 parts of beer yeast. The invention provides more comprehensive nutrition powder containing whole grains, beans, potatoes, nuts and the like, and further comprises common food with the effect of reducing blood sugar and medicinal and edible food which has the effect of reducing blood sugar and can prevent diabetic complications, and the nutrition flour has the following functions: balanced nutrition is provided for the body; blood sugar reduction is assisted; the islet cells are assisted to repair; and diabetic complications are prevented. The invention relates to an application of nutrition-balanced flour assisting in pancreas islet repair. The flour is used for making steamed buns, dumplings, steamed stuffed buns, wontons, noodles, cakes, biscuits or other flour products.

The invention discloses application of ANG in preparation of a medicine for preventing or treating diabetes mellitus. The application finds that ANG can inhibit the apoptosis of islet cells during pancreatitis, enhance the ability of islet cells to resist inflammation damage, and inhibit the sugar tolerance damage of an organism, so that the ANG is expected to improve the clinical prevention and treatment effects of diabetes.

The invention provides a high-stress-tolerance pancreas islet organ as well as a preparation method and application thereof. Specifically, the invention provides a method for preparing pancreas islet organs. The invention also provides a use of a reagent combination comprising (a) a pancreatic islet organ and (b) a compound of formula I or a pharmaceutically acceptable salt thereof. In the presence of the compound shown in the formula I or the pharmaceutically acceptable salt thereof, pancreatic endocrine progenitor cells are cultured, so that the increase of the differentiation proportion of pancreatic beta cells is promoted, and pancreatic islet organs with high stress tolerance are obtained; according to the present invention, the combination of the pancreatic islet organ and the compound represented by the formula I or the pharmaceutically acceptable salt thereof can significantly improve and alleviate the integration stress reaction generated during the pancreatic islet organ transplantation compared to the only transplantation treatment, such that the pancreatic islet beta cell identity loss is resisted, and the stress tolerance of the pancreatic islet organ is significantly improved; therefore, the invention provides a new strategy for the treatment of diabetes, and has a wide application prospect.

The invention relates to a preparation method and application of ganoderma lucidum and coix seed mycoplasm, and belongs to the technical field of traditional Chinese medicine and health food processing. According to the preparation method of the lucid ganoderma and coix seed mycoplasm, the lucid ganoderma and coix seed mycoplasm is obtained through liquid fermentation by taking coix seeds as a fermentation substrate and lucid ganoderma as a fermentation strain. The ganoderma lucidum and coix seed mycoplasm composition is obtained through a ganoderma lucidum and coix seed two-way fermentation technology, functional ingredients are increased, and the ganoderma lucidum and coix seed mycoplasm composition has the effects of enhancing immunity, protecting pancreas islet beta cells and improving glycolipid metabolism. The invention develops the application of the traditional Chinese medicine composition in the fields of food and health care products.

This invention relates to the regulation of pancreatic islet cell differentiation by regulatory factors related to N6-adenosine methylation modification of mRNA. Specifically, it relates to the use of (a) the ALKBH5 gene, or its protein, or its promoter; and / or (b) the YTHDF2 gene, or its protein, or its inhibitor, for the preparation of compositions or formulations for (1) promoting the differentiation of endodermal cells into pancreatic islet precursor cells and / or islet organoids; and / or (2) preventing and / or treating diabetes. The ALKBH5 of this invention regulates the N6-adenosine methylation modification of mRNA by... 6 Modification A controls the in vitro differentiation process of human pancreatic cells. Furthermore, the method of this invention holds promise as an effective method for in vitro culture of pancreatic islet cells, and could subsequently be applied to the treatment of diabetes.

The present invention belongs to the technical field of cell biology, and particularly relates to the application of Hippo-Yap pathway regulators in promoting the directed differentiation of induced pluripotent stem cells into pancreatic progenitor cells. The method of the present invention can efficiently obtain pancreatic progenitor cells derived from non-human primate rhesus monkeys in vitro, providing a material source for further obtaining functional pancreatic islet β cells of non-human primate rhesus monkeys, and more importantly, providing a practical basis for the autologous transplantation treatment of non-human primate diabetic animal models.

The invention relates to a device for distributing and receiving a population of pancreatic islets heterogeneous in size, the device comprising a matrix having a first face opposite a second face, characterized in that the matrix comprises concentric channels centered on a center O, the channels have an opening for receiving the pancreatic cells, the opening leading out onto the first face, the opening extending over the entire length (L) of the channel, the opening having a width (I) taken along the section Si, the device being configured such that the widths of the opening of two adjacent channels have an equal or increasing value moving away from the center O and such that the widths of the opening of a channel closest to the center O and of a channel furthest from the center O have an increasing value moving away from the center O. The invention relates to the field of implantable devices, in particular artificial pancreas devices.

The present invention discloses the application of Alternariol in the preparation of diabetes prevention and treatment drugs, which belongs to the field of medical technology. The present invention first screens out the compound Alternariol through in vitro DYRK1A kinase activity experiment, and its IC 50 The value was 20μM. Then, through INS-1 cell proliferation model experiments, it was found that the compound Alternariol can promote INS-1 cell proliferation and promote insulin secretion by pancreatic islet cells. Even at very low concentrations, such as 300nmol, it can significantly promote INS-1 cell proliferation. Finally, through mouse diabetes model experiments, it was further verified that the compound Alternariol can indeed control blood sugar in T1D mice and promote pancreatic proliferation in mice, while also having no toxic effects on the mouse body. This invention has extraordinary significance for T1B diabetes with impaired pancreatic cell function.

This invention discloses the application of IKK inhibitors in the preparation of drugs to restore pancreatic islet function. IKK inhibitors can effectively improve the problem of pancreatic β-cell differentiation defects, significantly increase the number of pancreatic β-cells, enhance the insulin secretion capacity of islet cells, and specifically upregulate the expression of key functional genes of pancreatic β-cells such as INS and NKX6.1 genes, thus repairing pancreatic islet function damage. This solves the technical problem that current treatments for type 1 diabetes can only replace insulin and relieve blood sugar symptoms, but cannot fundamentally repair pancreatic islet function. IKK inhibitors can be used to prepare drugs for the treatment of type 1 diabetes, providing a new approach for the clinical treatment of type 1 diabetes and possessing extremely high clinical translational value.

The present invention discloses a long-acting GGG triple-target agonist. The compound of the present invention simultaneously achieves excellent agonist ability at the nM level for the three targets of GLP-1 / GIP / GCGR, and can fully excite the corresponding target organ tissue cells. The compound of the present invention can promote insulin secretion and lower blood sugar; it can also inhibit food intake, delay gastric emptying, increase energy consumption, and ultimately observe a weight loss effect. The compound of the present invention can reduce pancreatic β-cell apoptosis, increase the number of pancreatic β-cells, and improve pancreatic cell function. The compound of the present invention can also improve blood lipids, reduce liver fat accumulation, and inhibit the development of liver inflammation. The compound or composition of the present invention can be used to prevent and / or treat metabolic disorders and related complications. The compound or composition of the present invention can be used to treat bone diseases related to endocrine diseases, metabolic disorders, kidney disease, etc., such as osteoporosis and osteoarthritis.

The present application relates to the technical field of mRNA vaccine, and specifically discloses a proinsulin mRNA vaccine for protecting the function and quantity of pancreatic beta cells. The vaccine is composed of a lipid nanoparticle (LNP) and an mRNA wrapped by the LNP; the mRNA is an mRNA sequence encoding proinsulin, and all uridines in the mRNA sequence are replaced by N1-methyl pseudouridine. The mRNA vaccine of the present application realizes the dual protection of the quantity and function of pancreatic beta cells, compared with the existing intervention means which only focus on blood glucose control or immune regulation, the present application delays the occurrence process of type 1 diabetes from the root, and provides a new technical scheme and drug selection for the prevention and early intervention of type 1 diabetes.

The invention provides a preparation process of mulberry, melon, fruit and vegetable protein paste for repairing islet cells and promoting insulin secretion, and relates to the technical field of hypoglycemic products. The prescription comprises a mulberry leaf extract, a bitter gourd extract, a white gourd extract, a cyclocarya paliurus extract, a sweet ampelopsis grossedentata extract, cucumbers, pumpkins, onions, corn stigma, lettuces, brassica juncea, asparagus, Chinese yams, radix puerariae, purple cabbages, broccoli, carrots, hericium erinaceus, black beans, white beans, zebra beans, hyacinth beans, cordyceps flowers, mushrooms, needle mushrooms, undaria pinnatifida, spirulina, leek seeds, lotus seeds, almonds, quinoa and spina date seeds. , chia seeds, pumpkin seeds, silkworm chrysalis and tenebrio molitor. The traditional Chinese medicine composition is prepared according to the traditional Chinese medicine theory and a scientific formula, and clinical verification shows that the traditional Chinese medicine composition has the effects of reducing blood sugar and blood fat, promoting digestion, invigorating the stomach, nourishing the liver and tonifying the kidney, can effectively improve and prevent diabetes mellitus, can also regulate gastrointestinal peristalsis and is helpful for regulating constipation. The prescription is simple to operate, low in cost and suitable for mass production.

Methods of using pulsed focused ultrasound (pFUS) therapy to treat pancreatic disorders such as type 1 diabetes, pancreatitis, and pancreatic cancer are provided. The methods utilize pulsed focused ultrasound (pFUS) therapy either by itself or in combination with islet transplantation and / or stem cell therapy to promote regeneration of damaged pancreatic tissue, increase insulin secretion in response to glucose, or improve engraftment and revascularization of transplanted islets or beta cells. Additionally, methods of using pFUS are provided for modulating paracrine secretion in the pancreas, islets, beta cells, or stem cells, or at a transplantation site to therapeutically alter levels of various factors including, without limitation, cytokines, growth factors, angiogenic factors, and cell adhesion molecules.

The embodiment of the invention provides a pancreas islet differentiation method and equipment for microencapsulated induced pluripotent stem cells, and relates to the field of stem cell differentiation. In order to solve the problems of low differentiation efficiency, low insulin secretion function and immunological rejection after transplantation of the two-dimensional cultured iPSC, a method for inducing the iPSC into the islet cells under a three-dimensional condition is constructed, the differentiation efficiency and the functions of the islet cells are improved, immune isolation transplantation can be directly performed after differentiation, and meanwhile, new equipment is constructed. The structure is beneficial to improving the mass transfer efficiency in the induction process, and large-scale and accurate condition control can be realized. The preparation method comprises the following steps: S1, mixing iPSC with a sodium alginate solution to form calcium alginate microspheres containing the iPSC; s2, culturing the iPSC in the calcium alginate microspheres obtained in the step S1 into a cell cluster; and S3, performing stage induced differentiation on the cell cluster obtained in the step S2 to obtain the endocrine cell cluster.

To provide a cell device that allows quicker induction of insulin secretion and suppression of insulin secretion from the initiation of operation, and also to provide a method for controlling insulin secretion.SOLUTION: A cell device 1 comprises: a culture vessel 2; a medium 3 and pancreatic β-cells 4 accommodated in the culture vessel 2; a working electrode 5, to which the pancreatic β-cells 4 adhere and which contains PEDOT:PzSS; a counter electrode 6 provided so as to be in contact with the medium 3; and a potential-application section 8 that applies a potential to the pancreatic β-cells 4 by means of the working electrode 5 and the counter electrode 6.SELECTED DRAWING: Figure 3

The present invention relates to a test kit for performing an assay to detect and measure at least one autoantibody molecule in a subject developing type 1 diabetes (T1D). The invention more specifically relates to a recombinant antigen molecule fused to a bioluminescent reporter protein to detect an autoantibody molecule against a self-antigen. Said self-antigen is preferably expressed by pancreatic islet beta cells and include insulin, proinsulin, Glutamate decarboxylase 65, islet antigen 2, and Zinc transporter 8. More specifically, the present invention relates to an assay comprising a set of at least three recombinant antigen molecules in a single composition, the antigen molecules being selected from the list comprising recombinant human Glutamate decarboxylase 65, recombinant human islet antigen 2, recombinant human Zinc transporter 8, recombinant human insulin, and recombinant human proinsulin. The invention further relates to methods for determining the presence and / or level of at least one autoantibody molecule in a sample from a human subject developing T1D using said recombinant antigen molecules. According to the invention, the presence, absence, or amount of one or more autoantibody molecules against said self-antigens is determined with a luciferase immune precipitation system (LIPS) assay or a modified version of a LIPS assay, i.e., a solid phase capture LIPS (scLIPS) assay.

The invention discloses a method for efficiently and directionally inducing IPS to be differentiated into pancreatic beta cells. According to the method, through staged signal regulation and strict cell screening, the directionality and the overall efficiency of differentiation are remarkably improved. The whole process pays attention to cell quality control from the initial stage, and a stable foundation is laid for subsequent differentiation by screening iPS cells with uniform morphology and high expression of pluripotent markers. Progressive signal molecule regulation is adopted in each stage, and an accurate differentiation path is formed from Activin A gradient adjustment during endoderm induction, synergistic effect of FGF10 and retinoic acid in pancreatic precursor cell differentiation and Wnt signal inhibition during endocrine precursor cell induction, so that the non-specific differentiation tendency is effectively reduced. Meanwhile, cell enrichment steps of key nodes, such as SOX17 positive cell screening in an endoderm stage and Ngn3 magnetic bead sorting of endocrine precursor cells, further improve the purity of a target cell population and avoid interference of parenchyma cells on subsequent function maturation.

The invention discloses a stem cell medicine for pancreas islet repair and application, and belongs to the technical field of stem cell biology, and the stem cell medicine for pancreas islet repair is prepared by compounding a carrier, pancreatic progenitor cells and pancreas islet-like cells in proportion. The problems that in the prior art, due to the fact that stem cells are unstable in differentiation efficiency, poor in synergistic effect and poor in biocompatibility, islet injury cannot be repaired, and diabetes cannot be treated are solved. According to the present invention, the dual mechanisms of endogenous beta cell repair and exogenous beta cell supplement are adopted, and the beta cell function recovery and the group structure reconstruction are synchronously achieved through the reasonable ratio, such that the in-vivo blood glucose of the mouse is significantly reduced, the beta cell number and the glucose tolerance dose of the mouse are increased, and the low immunogenicity and the high anti-inflammatory property are simultaneously provided. The compound can be used for treating type I and type II diabetes mellitus, improving the insulin secretion function and relieving local inflammatory response of pancreas by promoting pancreas islet beta cell proliferation, and has application potential in treatment of type I and type II diabetes mellitus and pancreas islet repair.

The invention discloses an immune tolerance realization method based on immune cell negative selection, which comprises the following steps: step 1, separating mononuclear cells from peripheral blood of a patient, and inducing and differentiating the mononuclear cells into DCs in vitro; 2, introducing the Aire gene into DCs by using a virus vector adeno-associated virus (AAV) or a lentivirus; 3, over-expressing Aire protein by the modified DCs, so that the modified DCs can express a plurality of autoantigens; and step 4, injecting the DCs subjected to Aire overexpression back into the body of the patient, and inducing immune tolerance. The preparation method has the beneficial effects that the immune regulation function of DCs is enhanced through the Aire gene, the activity of autoreactive T cells is inhibited, and the damage to pancreatic beta cells is reduced; dependence on a traditional immunosuppressor is reduced, and side effects are reduced; a novel treatment method is provided for autoimmune diseases such as type 1 diabetes, and high safety and specificity are achieved.

The invention relates to the technical field of biology, in particular to application of SAFit2 in preparation of a reagent for improving pancreas islet dysfunction. The invention discovers that SAFit2 has a remarkable improvement effect on insulin secretion dysfunction in a high-glucose and high-fat induced islet injury model. Experiments show that in a high glucose (33 mM) combined palmitic acid (500 [mu] M) injury model, the SAFit2 can significantly improve the insulin secretion function of the pancreas islet. Specifically, the SAFit2 is pretreated, the glucose stimulated insulin secretion (GSIS) index of the pancreas islet and the intracellular insulin content are remarkably increased, insulin secretion under high glucose stimulation is promoted, and the SAFit2 is proved to have the effect of promoting the insulin secretion function of the pancreas islet beta cells.

The invention provides a preparation method and application of an anti-IL-11 antibody modified Treg cell, and belongs to the technical field of genetic engineering.The preparation method of the anti-IL-11 antibody modified Treg cell comprises the steps that after the Treg cell and umbilical cord blood pluripotent stem cells are co-cultured, the Treg cell is separated and recycled, an anti-IL-11 antibody is adopted for modification, and the anti-IL-11 antibody modified Treg cell is obtained; the nucleotide sequence of the anti-IL-11 antibody is as shown in SEQ ID NO. 2 in the sequence table. In the co-culture process, stem cells are used for providing an immune microenvironment, promoting Treg cell amplification and enhancing the inhibition ability of Treg cells, and obtaining the specific recognition ability of pancreas islet beta cell antigens, so that autoimmune attacks are inhibited more accurately; the nucleotide sequences of the heavy chain and the light chain of the anti-IL-11 antibody are optimized, and the anti-IL-11 antibody has higher efficacy in treatment of diabetic mice.

The invention discloses application of pancreatic protein peptide in preparation of products for improving insulin resistance and repairing pancreatic functions, and relates to the technical field of biological medicines. The pancreatic-derived protein peptide is extracted and purified from porcine pancreatic tissue through a specific enzymolysis process, the molecular weight is concentrated at 800-2000Da, and the pancreatic-derived protein peptide contains 12 essential amino acids. Experiments prove that the protein peptide can significantly improve insulin sensitivity and promote pancreatic beta cell proliferation through oral administration or intraperitoneal injection, and has no obvious toxic or side effect. The invention provides a novel treatment means for diseases related to type 2 diabetes and pancreatic function impairment, and has a wide clinical application prospect.